|
|
Volumn 92, Issue 8, 2000, Pages 596-
|
|
NCI-Myriad agreement offers BRCA testing at reduced cost.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BRCA2 PROTEIN;
TRANSCRIPTION FACTOR;
TUMOR PROTEIN;
ARTICLE;
BIOTECHNOLOGY;
COST;
DNA SEQUENCE;
ECONOMICS;
GENETIC SCREENING;
GENETICS;
HEALTH CARE ORGANIZATION;
PATENT;
TUMOR SUPPRESSOR GENE;
UNITED STATES;
BIOTECHNOLOGY;
BRCA2 PROTEIN;
COSTS AND COST ANALYSIS;
GENES, BRCA1;
GENETIC SCREENING;
NATIONAL INSTITUTES OF HEALTH (U.S.);
NEOPLASM PROTEINS;
PATENTS;
SEQUENCE ANALYSIS, DNA;
TRANSCRIPTION FACTORS;
UNITED STATES;
|
|
EID: 0034685336
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/92.8.596 Document Type: Article |
|
Times cited : (9)
|
|
References (0)
|
